gilead sciences inc asked us house democrats explain company set 8400 price hepatitis c treatment sovaldi
lawmakers also asked gilead chief executive officer john martin explain done make sure medicine gets hands lowincome patients especially governmentrun health programs
concern treatment cure patients cannot afford democratic representatives henry waxman california frank pallone jr new jersey diana degette colorado wrote letter sent yesterday lawmakers asked gilead brief congress april 3
gileads drug approved last year breakthrough treatment viral liver infection medicine offers higher cure rates fewer side effects older treatments high cost attracted scrutiny resistance insurers public health advocates
letter bank shot gets things going goal getting gilead significantly lower price sovaldi terry haines senior political strategist isi group llc said note clients letter may starting point campaign pressure foster city californiabased gilead encourage republicans senators parties join effort said
gilead declined 46 percent 7207 4 pm new york time nasdaq biotechnology index 121 companies fell 44 percent
letter democrats asked gilead explain drug priced discounts made available lowincome patients government health programs potential impact public health insurers blocking delaying access medicine cost
drugmaker said meet waxman members congress
heard concerns raised letter reached number members congress prior letter address concerns gilead said statement working number stakeholders including federal state officials share scientific medical evidence
democrats minority house representatives impact effort may minimal said justin simon analyst height securities llc washington unlikely affect price currently marketed priced products said
